Highest-materiality recent filing
Beyond Air receives Nasdaq delisting notice for bid price non-compliance; hearing requested
Nasdaq Staff notified Beyond Air that its common stock failed to maintain minimum $1.00 bid price per Listing Rule 5550(a)(2).
Nasdaq notified Beyond Air on Apr 7, 2026 that it fails Bid Price Rule; stock closed below $1 for 30 consecutive business days through Apr 6.
Beyond Air CEO Steve Lisi resigns; Robert Goodman appointed CEO effective March 27, 2026
Steve Lisi resigned as CEO and director, effective March 27, 2026; no disagreement with the Company.
Beyond Air Q3 revenue up 105% to $2.2M, net loss narrows; FY2026 guidance reaffirmed at $8-10M
Revenue $2.2M, up 105% YoY; gross profit $0.3M vs ($0.2M) gross loss prior year.
Beyond Air raises $5M in private placement of stock and warrants at $1.272/unit
Gross proceeds of $5.0M from sale of 3,930,818 shares (or pre-funded warrants) and five-year warrants at $1.147 strike.
XTL to acquire 85% of Beyond Air's NeuroNOS for equity, $1M cash, up to $32.5M milestones
XTL acquires 85% of NeuroNOS for 19.9% of XTL's share capital, $1M cash, and up to $32.5M in milestone payments.
Beyond Air Q2 revenue up 128% to $1.8M; net loss narrows; secures $32M financing
Revenue $1.8M (+128% YoY); net loss ($7.9M) ($1.25/share) vs. ($13.4M) ($5.67/share).
Beyond Air secures up to $32M in financing from Streeterville Capital
Issued $12M promissory note with 15% annual interest; net proceeds ~$12M; $6M placed in restricted account.
Beyond Air receives ~$3.25M from warrant exercise; issues new warrants for 719,561 shares
Gross proceeds ~$3.25M from immediate exercise of 1,439,126 existing warrants at reduced price of $2.21/share.
NeuroNOS (Beyond Air unit) receives FDA Orphan Drug Designation for BA-101 in glioblastoma
FDA grants Orphan Drug Designation for BA-101, an investigational nNOS inhibitor, for treatment of glioblastoma.
Beyond Air Q1 revenue rises 157% to $1.8M; net loss narrows to $7.7M
Revenue $1.8M vs $0.7M YoY (+157%); gross profit $0.2M vs loss of $0.3M.
Beyond Air announces 1-for-20 reverse stock split to regain Nasdaq compliance
Reverse stock split ratio 1-for-20, effective July 14, 2025.
Beyond Air shareholders approve reverse stock split at up to 1-for-50 ratio
Shareholders approved reverse stock split ratio between 1-for-10 and 1-for-50, as determined by the Board.
Beyond Air Q4/FY2025 revenue $3.7M (+220% YoY); guides FY2026 $12-16M; filed PMA for LungFit PH II
Revenue $3.7M for FY2025, up 220% YoY; net loss $46.6M ($0.69 per share).
On June 16, 2025, the Board of Directors (the “Board”) of the Company appointed Robert Goodman as a member of the Board.
Max materiality 0.80 · Median 0.65 · Most common event other_material